Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Is the Estimated Industry Valuation for the Breast Cancer Gene (BRCA) Mutations Treatment Sector?#_x000D_
Over the years, the market size for the treatment of mutations in the breast cancer gene (BRCA) has exhibited robust growth. It’s projected to escalate from $4.67 billion in 2024 to $5.01 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The growth during the historical period can be owed to several factors. These include the increasing accessibility of genetic testing, enhanced government and private support for oncology research, growing need for personalized medicine, increased acceptance of preventive healthcare measures, and a rise in the number of at-risk population opting for screening._x000D_
_x000D_
The market size for the treatment of breast cancer gene (BRCA) mutations is anticipated to expand considerably in the coming years. Projected growth is a compound annual growth rate (CAGR) of 7.0%, reaching $6.56 billion in value by 2029. The factors driving this projected expansion over the forecast period include increased integration of genetic testing in insurance plans, a surging demand for companion diagnostics, a greater emphasis on screening programs for hereditary cancer, a rise in clinical trials specific to BRCA-related cancers, and growing adoption of preventive surgery procedures. Key trends for this period include advancements in gene editing technology, novel non-invasive diagnostic methods, use of artificial intelligence and machine learning in genetic risk analysis, progress in liquid biopsy applications for BRCA-linked cancers, and innovative personalized treatment algorithms._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp_x000D_
_x000D_
#What Forces Are Driving The Growth Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_
The growth of the breast cancer gene (BRCA) mutation treatment market is anticipated to be driven by the escalating demand for targeted therapies. These therapies are unique medical treatments that directly target cancer cells by focusing on the genetic mutations or proteins that aid cancer growth. The increased demand for such therapies comes from their unique ability to precisely target the cells or molecules that cause diseases, thereby reducing harm to healthy tissues. Their precision results in enhanced effectiveness of treatment and lesser side effects in comparison to conventional therapies. In the context of breast cancer gene (BRCA) mutations, targeted therapies facilitate the provision of precision medicines tailored to tackle the specific genetic variations fueling the disease. This results in better treatment outcomes and lesser unnecessary side effects. For example, a report published in July 2023 by the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, revealed that at the end of Q1 2023, there were 247 gene therapies in Phase II. This number increased by 5% to reach 260 by the end of Q2 2023. Thus, the growing demand for targeted therapies serves as a key driver for the growth of the breast cancer gene (BRCA) mutation treatment market._x000D_
_x000D_
#How Is The Breast Cancer Gene (BRCA) Mutations Treatment Industry Segmented Across Key Parameters?#_x000D_
The breast cancer gene (BRCA) mutations treatment market covered in this report is segmented_x000D_
_x000D_
1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy_x000D_
2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer_x000D_
3) By Administration Route: Oral, Intravenous, Subcutaneous_x000D_
4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics_x000D_
_x000D_
Subsegments:_x000D_
1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors_x000D_
2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites_x000D_
3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists_x000D_
4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive Cell Transfer (ACT)_x000D_
_x000D_
#What Notable Trends Are Shaping The Direction Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_
Leading entities in the BRCA (breast cancer gene) mutation treatment market are concentrating their efforts on the advancement of superior solutions, including adjuvant therapy, with an aim to boost treatment efficacy and augment patient results. This adjuvant procedure is an additional therapy applied after the principal treatment to eliminate any residual cancer cells, reducing the possibility of recurrence and thereby improving overall therapy performance and patient survival rates. For example, AstraZeneca plc, a biotechnology enterprise based in the UK, alongside Merck & Co., Inc., a pharmaceutical company in the US, introduced LYNPARZA (olaparib) in August 2022. The European Commission approved this for adult patients with germline BRCA mutations, HER2-negative high-risk initial-stage breast cancer. LYNPARZA can thus be used as a single treatment or combined with endocrine therapy for patients who have undergone prior neoadjuvant or adjuvant chemotherapy. This approval was achieved based on the phase 3 OlympiA trial’s results, which revealed a major enhancement in disease-free and overall survival, significantly diminishing the threat of breast cancer recurrence or death._x000D_
_x000D_
#Which Companies Currently Dominate The Competitive Landscape In The Breast Cancer Gene (BRCA) Mutations Treatment Industry?#_x000D_
Major companies operating in the breast cancer gene (BRCA) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#Which Geographic Regions Are Driving Demand In The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_
North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model